Acne Therapeutics Market Is Segmented By Type( Comedonal, Inflammatory, Cystic, Postsurgical/wound), By Therapeutic Class (Retinoid, Antibiotic, Hormonal Agent, Combination, Others), By Route of Administration (Topical, Oral, Injectable), By Distribution Channel (Retail Store, Pharmacy & Drug Store, Online Store) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Acne Therapeutics Market Overview
The global acne therapeutics market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.7% during the forecast period (2023-2030).
Adolescence is the most common time for acne, an inflammatory condition of the pilosebaceous units. Open (black) and closed (white) comedones, inflammatory papules, pustules, nodules, and cysts are the distinctive lesions that may result in scarring and pigmentary alterations. Acne's multifactorial pathophysiology includes aberrant follicular keratinization, increased sebum production by hyperandrogenism, Propionibacterium acnes growth, and inflammation.
Acne Therapeutics Market Scope and Summary
| Metrics | Details |
| Market CAGR | 4.7% |
| Segments Covered | By Type, By Therapeutic Class, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Acne Therapeutics Market Dynamics
The major factors driving the global acne therapeutics market are the increasing desire for quicker treatment and better results, increasing incidence of acne-related conditions and the usage of various acne treatment products, including antibiotics and retinoids, and the growing awareness of the condition further influence the market.
An increasing desire for quicker treatment and better results is expected to drive the market’s growth.
As patients expect more expedient therapies and effective outcomes, the need for equipment-based therapies like lasers is anticipated to rise. Laser procedures prevent the recurrence of issues, including increased facial hair growth and pigmentation abnormalities and their future occurrence. Additionally, patients might adapt more easily to laser treatments because they are less uncomfortable than other forms. For instance, doctors advise utilizing combination medication to permanently reduce the development of acne, such as pairing a topical antibiotic with a retinoid.
Dermatology Times, 2022 reports the recent clearance of the AviClear laser, which targets sebaceous glands and is the first device certified by the US Food and Drug Administration (FDA) for mild-to-severe, has enhanced the energy-based therapy of acne. Studies have shown that electro thermolysis is a secure and efficient way of treating acne by selectively destroying sebaceous glands. According to a randomized, controlled research including 63 patients, the treatment group, which underwent three electro thermolysis treatments spaced four weeks apart, experienced a significant decrease in inflammatory acne lesions at week 12, as determined by two independent physicians. Such investigations paved the way for using energy-based devices to treat acne. "The most recent developments in device-based acne treatment use wavelengths unique to sebum.
Side effects associated with acne therapeutics are expected to hamper the market’s growth.
Additionally, patients switching to other options and the adverse effects of the already accessible treatments may be contributing factors to the market's slow revenue growth.
COVID-19 Impact Analysis on Acne Therapeutics Market
The COVID-19 outbreak originated in China and has spread far over the world. Nearly all countries are affected by the pandemic. As most nations implemented lockdowns to battle the pandemic, this affects the acne therapeutics market. The pandemic has slowed down economic expansion across a wide range of industries. The covid has put a strain on healthcare systems worldwide, and many dermatology clinics are no longer accessible to the public due to safety concerns.
For the treatment and isolation of patients with the covid infection, several hospitals and clinics have been modified into Covid-19 centers using pandemic-approved hospital structures. The lockdown also prevents many patients from getting to pharmacies and dermatologist offices to pick up their prescriptions. Telemedicine has become a viable and effective way to deliver crucial dermatological services to acne patients in the contemporary environment.
Acne Therapeutics Market Segment Analysis
The retinoid segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
The market for acne treatments is anticipated to be dominated by the retinoid segment. The demand for retinoid creams and gels has surged since they successfully treat or prevent mild to moderate acne. After a successful treatment, they can also be used as maintenance therapy to keep the skin clear. Additionally, market participants constantly introduce brand-new and generic retinoids to acquire a competitive edge in the market.
For instance, in March 2022, Twyneo, a cream with tretinoin 0.1% and benzoyl peroxide 3.0%, was approved by the FDA for the topical treatment of acne vulgaris in patients 9 years of age and older. Twyneo is a fixed-dose mixture of the topical antibiotic benzoyl peroxide and the retinoid tretinoin 0.1%. To include the two active ingredients in the cream, Twyneo's formulation uses silica core-shell structures to independently microencapsulate the tretinoin and benzoyl peroxide crystals. The increasing number of retinoid product launches will result in more adoption because of their effectiveness in treating acne, which is anticipated to propel the expansion of this market.
Throughout the projection period, increased research and development for discontinued acne therapies will also benefit expanding this market. For instance, in April 2021, Ortho Dermatologics, a division of Bausch Health specializing in prescription dermatology, released encouraging topline results from its second Phase III trial for IDP-126, a three-compound combination gel tested on 193 people with acne vulgaris. The results showed reductions in both inflammatory and non-inflammatory lesions at week 12 in both conditions. Adapalene, retinol, and the antimicrobial benzoyl peroxide are all included in IDP-126. Such retinoid-related research is anticipated to help the segment's growth by increasing sales and manufacturing of related items.
Acne Therapeutics Market Geographical Analysis
North America holds the largest market share in the global acne therapeutics market.
North America dominates the global acne therapeutics market primarily due to its large population, excellent medical infrastructure, and high-income levels. The key drivers propelling the growth of the acne therapeutics market in North America are the rising prevalence of acne in the region, acquisitions, and recent product introductions. In order to compete with those already on the market, a significant number of key market players are developing new products and technologies, while others are acquiring or partnering with other companies that are in high demand in the acne therapeutics market.
For instance, in December 2021, Sanofi announced an agreement to buy Origimm Biotechnology GmbH, a privately held biotechnology business based in Austria that specializes in identifying pathogenic skin microbiome components and antigens from bacteria that cause skin conditions, including acne. By making this acquisition, Sanofi is continuing to implement its global Play to Win strategy, look for growth possibilities, and develop a portfolio of vaccines that leads the market.
For instance, in November 2021, the US market for Winlevi cream used to treat acne in individuals 12 years of age and older was announced by Sun Pharmaceutical Industries. Winlevi, a topical androgen receptor inhibitor that is the first of its kind, received FDA approval in August 2020. According to a statement from Sun Pharma, Winlevi is the first FDA-approved acne medication with the first-in-class mechanism of action in nearly 40 years. It prevents the effects of androgen receptors in sebaceous gland cells, which are responsible for creating sebum (oil) and irritation in the skin. It is appropriate for both genders. Therefore, it is anticipated that the market under study in the North American area will be driven by regular product launches and research and development initiatives undergoing the creation of novel acne therapies.
Acne Therapeutics Market Companies & Competitive Landscape
The acne therapeutics market is moderately competitive with local and global companies’ presence Sun Pharmaceutical Industries, Inc, Allergan Plc, Galderma S.A, Johnson & Johnson, Reckitt Benckiser Group, Guthy-Renker, Stiefel Laboratories, Valeant Pharmaceuticals
Teva Pharmaceuticals, Cutera Inc, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in March 2022, The U.S. Food and Drug Administration cleared AviClear, the first and only energy-based device to do so for the treatment of mild, moderate, and severe acne. CUTERA, INC. ("Cutera" or the "Company"), a leading developer of dermatology solutions, released the news.
Sun Pharmaceutical Industries, Inc.
Overview: An extensive selection of pharmaceutical formulations, including branded generics and generic medications, are offered by Sun Pharmaceutical Industries Ltd. (Sun Pharma), a specialty pharmaceutical company. Products for the treatment of psychiatric, neurological, nephrological, gastroenterological, Orthopedic, and ophthalmologic diseases and disorders, as well as cardiac problems, are part of the company's portfolio.
Product Portfolio:
ABSORICA LD (isotretinoin): Under fed conditions, ABSORICA LD 32 mg is bioequivalent to ABSORICA 40 mg. Additionally, ABSORICA LD has a similar safety profile while providing twice the absorption of ABSORICA in a fasting condition. ABSORICA LD is not interchangeable with any other isotretinoin that is currently on the market and offers maximum isotretinoin absorption at a 20% lower dose.
The global acne therapeutics market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.
